Literature DB >> 29108094

Dimethyl fumarate treatment alters NK cell function in multiple sclerosis.

Matthew D Smith1, Peter A Calabresi1, Pavan Bhargava1.   

Abstract

Dimethyl fumarate (DMF) treatment in multiple sclerosis (MS) increased the proportion of immunoregulatory CD56bright NK cells and this change was proportional to reductions in CD8+ memory T cells. DMF and monomethyl fumarate (MMF) treatment in vitro had directs effects on NK cells and promoted degranulation and cytotoxicity.
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  CD155; CD56; Dimethyl fumarate; Multiple Sclerosis; NK cells

Mesh：

Substances：

Year:  2017        PMID： 29108094     DOI： 10.1002/eji.201747277

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN： 0014-2980            Impact factor:   5.532


  13 in total

Review 1.  Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis.

Authors:  Sudhir Kumar Yadav; Devika Soin; Kouichi Ito; Suhayl Dhib-Jalbut
Journal:  J Mol Med (Berl)       Date:  2019-02-28       Impact factor: 4.599

2.  KIR2DL4-HLAG interaction at human NK cell-oligodendrocyte interfaces regulates IFN-γ-mediated effects.

Authors:  P P Banerjee; L Pang; S S Soldan; S M Miah; A Eisenberg; S Maru; A Waldman; E A Smith; Y Rosenberg-Hasson; D Hirschberg; A Smith; D V Ablashi; K S Campbell; J S Orange
Journal:  Mol Immunol       Date:  2018-11-24       Impact factor: 4.407

Review 3.  Lactate modulation of immune responses in inflammatory versus tumour microenvironments.

Authors:  Michelangelo Certo; Chin-Hsien Tsai; Valentina Pucino; Ping-Chih Ho; Claudio Mauro
Journal:  Nat Rev Immunol       Date:  2020-08-24       Impact factor: 53.106

Review 4.  Alcohol and multiple sclerosis: an immune system-based review.

Authors:  Maryam Fahim; Aryan Rafiee Zadeh; Pouria Shoureshi; Keyvan Ghadimi; Masoumeh Cheshmavar; Neda Sheikhinia; Mahdieh Afzali
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2020-04-15

Review 5.  Immunological Aspects of Approved MS Therapeutics.

Authors:  Paulus S Rommer; Ron Milo; May H Han; Sammita Satyanarayan; Johann Sellner; Larissa Hauer; Zsolt Illes; Clemens Warnke; Sarah Laurent; Martin S Weber; Yinan Zhang; Olaf Stuve
Journal:  Front Immunol       Date:  2019-07-11       Impact factor: 7.561

Review 6.  The immunologic Warburg effect: Evidence and therapeutic opportunities in autoimmunity.

Authors:  Michael D Kornberg
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2020-02-27

7.  Dimethyl Fumarate as the Peripheral Blood Inflammatory Mediators Inhibitor in Prevention of Streptozotocin-Induced Neuroinflammation in Aged Rats.

Authors:  Danuta Wrona; Irena Majkutewicz; Grzegorz Świątek; Joanna Dunacka; Beata Grembecka; Wojciech Glac
Journal:  J Inflamm Res       Date:  2022-01-06

8.  Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis.

Authors:  Peter J Darlington; Brandon Stopnicki; Tarik Touil; Jean-Sebastien Doucet; Lama Fawaz; Morgan E Roberts; Marie-Noëlle Boivin; Nathalie Arbour; Mark S Freedman; Harold L Atkins; Amit Bar-Or
Journal:  Front Immunol       Date:  2018-05-07       Impact factor: 7.561

9.  Increased NK Cell Count in Multiple Sclerosis Patients Treated With Dimethyl Fumarate: A 2-Year Longitudinal Study.

Authors:  Damiano Marastoni; Alessandro Buriani; Anna Isabella Pisani; Francesco Crescenzo; Carmela Zuco; Stefano Fortinguerra; Vincenzo Sorrenti; Bruno Marenda; Chiara Romualdi; Roberta Magliozzi; Salvatore Monaco; Massimiliano Calabrese
Journal:  Front Immunol       Date:  2019-07-19       Impact factor: 7.561

Review 10.  CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis.

Authors:  Alice Laroni; Antonio Uccelli
Journal:  J Clin Med       Date:  2020-05-13       Impact factor: 4.241
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.